User login
AGA journals select new editorial fellows
which runs from July 2021 through June 2022. The AGA editorial fellowship program is in its fourth year.
- Amisha Ahuja, MD (Gastroenterology)
- Helenie Kefalalkes, MD (Gastroenterology)
- Katherine Falloon, MD (CGH)
- Judy Trieu, MD, MPH (CGH)
- Lindsey Kennedy, PhD (CMGH)
- Vivian Ortiz, MD (CMGH)
- Sagarika Satyavada, MD (TIGE)
- Eric Swei, MD (TIGE)
which runs from July 2021 through June 2022. The AGA editorial fellowship program is in its fourth year.
- Amisha Ahuja, MD (Gastroenterology)
- Helenie Kefalalkes, MD (Gastroenterology)
- Katherine Falloon, MD (CGH)
- Judy Trieu, MD, MPH (CGH)
- Lindsey Kennedy, PhD (CMGH)
- Vivian Ortiz, MD (CMGH)
- Sagarika Satyavada, MD (TIGE)
- Eric Swei, MD (TIGE)
which runs from July 2021 through June 2022. The AGA editorial fellowship program is in its fourth year.
- Amisha Ahuja, MD (Gastroenterology)
- Helenie Kefalalkes, MD (Gastroenterology)
- Katherine Falloon, MD (CGH)
- Judy Trieu, MD, MPH (CGH)
- Lindsey Kennedy, PhD (CMGH)
- Vivian Ortiz, MD (CMGH)
- Sagarika Satyavada, MD (TIGE)
- Eric Swei, MD (TIGE)
Get to know 2021 award winners
David Y. Graham, MD – William Beaumont Prize in Gastroenterology
A remarkable clinician, scientist, and mentor to the next generation of GI, Dr. Graham currently serves as professor of medicine-gastroenterology at Baylor College of Medicine in Houston, Texas.
Dr. Graham was born in Ancon, in the Panama Canal Zone, where his father was working as an engineer. The family eventually settled in Lake Jackson, a small gulf coast town outside of Houston. There he developed a love for outdoor activities including hunting, fishing, and riding horses. He received a bachelor’s degree from the University of Notre Dame and returned home to Houston to receive his medical degree with honors from Baylor College of Medicine. Dr. Graham’s training was interrupted by the Vietnam War during which he was drafted into the U.S. Army as a flight surgeon.
In addition to his clinical and research missions, Dr. Graham has mentored numerous individuals during his years as a clinician scientist, many of whom have gone on to have successful careers in academic medicine. He has been an active AGA member for more than 4 decades, receiving several honors including the prestigious AGA Mentor Award in 2015 and the Janssen Award for Special Achievement in Gastroenterology.
Read more about Dr. Graham’s life and contribution to the GI community in a commentary in Gastroenterology written by Fasiha Kanwal, MD, and Hashem B. El-Serag, M, MPH.
Kim E. Barrett, PHD, AGAF – Distinguished Achievement Award in Basic Science
Dr. Kim E. Barrett is the 2021 recipient of the AGA Distinguished Achievement Award in Basic Science for her outstanding contributions to understanding mechanisms and regulation of intestinal epithelial transport and barrier function. She currently serves as distinguished professor of medicine at the University of California, San Diego, and is serving as a rotating appointment as director of the Division of Graduate Education of the National Science Foundation.
Born in London, Dr. Barrett was the first of her family to attend college. She earned a BSc in Medicinal Chemistry at University College London where she also stayed to complete her PhD studies. Following the completion of her PhD, Dr. Barrett moved to the U.S. to continue her training at the National Institutes of Health, where she continued her work in studies on the functional heterogeneity of mast cells. Alongside her many contributions to the GI field, she still believes in having fun, living by the phrase “put yourself about a bit.” She is a proud member of the band GI Distress as one of the “Fabulous Fasebettes.”
Read more about Dr. Barrett’s contributions to the GI community in a commentary in Gastroenterology, written by Mark Donowitz, MD, and Stephen Keely, MD.
David Y. Graham, MD – William Beaumont Prize in Gastroenterology
A remarkable clinician, scientist, and mentor to the next generation of GI, Dr. Graham currently serves as professor of medicine-gastroenterology at Baylor College of Medicine in Houston, Texas.
Dr. Graham was born in Ancon, in the Panama Canal Zone, where his father was working as an engineer. The family eventually settled in Lake Jackson, a small gulf coast town outside of Houston. There he developed a love for outdoor activities including hunting, fishing, and riding horses. He received a bachelor’s degree from the University of Notre Dame and returned home to Houston to receive his medical degree with honors from Baylor College of Medicine. Dr. Graham’s training was interrupted by the Vietnam War during which he was drafted into the U.S. Army as a flight surgeon.
In addition to his clinical and research missions, Dr. Graham has mentored numerous individuals during his years as a clinician scientist, many of whom have gone on to have successful careers in academic medicine. He has been an active AGA member for more than 4 decades, receiving several honors including the prestigious AGA Mentor Award in 2015 and the Janssen Award for Special Achievement in Gastroenterology.
Read more about Dr. Graham’s life and contribution to the GI community in a commentary in Gastroenterology written by Fasiha Kanwal, MD, and Hashem B. El-Serag, M, MPH.
Kim E. Barrett, PHD, AGAF – Distinguished Achievement Award in Basic Science
Dr. Kim E. Barrett is the 2021 recipient of the AGA Distinguished Achievement Award in Basic Science for her outstanding contributions to understanding mechanisms and regulation of intestinal epithelial transport and barrier function. She currently serves as distinguished professor of medicine at the University of California, San Diego, and is serving as a rotating appointment as director of the Division of Graduate Education of the National Science Foundation.
Born in London, Dr. Barrett was the first of her family to attend college. She earned a BSc in Medicinal Chemistry at University College London where she also stayed to complete her PhD studies. Following the completion of her PhD, Dr. Barrett moved to the U.S. to continue her training at the National Institutes of Health, where she continued her work in studies on the functional heterogeneity of mast cells. Alongside her many contributions to the GI field, she still believes in having fun, living by the phrase “put yourself about a bit.” She is a proud member of the band GI Distress as one of the “Fabulous Fasebettes.”
Read more about Dr. Barrett’s contributions to the GI community in a commentary in Gastroenterology, written by Mark Donowitz, MD, and Stephen Keely, MD.
David Y. Graham, MD – William Beaumont Prize in Gastroenterology
A remarkable clinician, scientist, and mentor to the next generation of GI, Dr. Graham currently serves as professor of medicine-gastroenterology at Baylor College of Medicine in Houston, Texas.
Dr. Graham was born in Ancon, in the Panama Canal Zone, where his father was working as an engineer. The family eventually settled in Lake Jackson, a small gulf coast town outside of Houston. There he developed a love for outdoor activities including hunting, fishing, and riding horses. He received a bachelor’s degree from the University of Notre Dame and returned home to Houston to receive his medical degree with honors from Baylor College of Medicine. Dr. Graham’s training was interrupted by the Vietnam War during which he was drafted into the U.S. Army as a flight surgeon.
In addition to his clinical and research missions, Dr. Graham has mentored numerous individuals during his years as a clinician scientist, many of whom have gone on to have successful careers in academic medicine. He has been an active AGA member for more than 4 decades, receiving several honors including the prestigious AGA Mentor Award in 2015 and the Janssen Award for Special Achievement in Gastroenterology.
Read more about Dr. Graham’s life and contribution to the GI community in a commentary in Gastroenterology written by Fasiha Kanwal, MD, and Hashem B. El-Serag, M, MPH.
Kim E. Barrett, PHD, AGAF – Distinguished Achievement Award in Basic Science
Dr. Kim E. Barrett is the 2021 recipient of the AGA Distinguished Achievement Award in Basic Science for her outstanding contributions to understanding mechanisms and regulation of intestinal epithelial transport and barrier function. She currently serves as distinguished professor of medicine at the University of California, San Diego, and is serving as a rotating appointment as director of the Division of Graduate Education of the National Science Foundation.
Born in London, Dr. Barrett was the first of her family to attend college. She earned a BSc in Medicinal Chemistry at University College London where she also stayed to complete her PhD studies. Following the completion of her PhD, Dr. Barrett moved to the U.S. to continue her training at the National Institutes of Health, where she continued her work in studies on the functional heterogeneity of mast cells. Alongside her many contributions to the GI field, she still believes in having fun, living by the phrase “put yourself about a bit.” She is a proud member of the band GI Distress as one of the “Fabulous Fasebettes.”
Read more about Dr. Barrett’s contributions to the GI community in a commentary in Gastroenterology, written by Mark Donowitz, MD, and Stephen Keely, MD.
New Clinical Practice Update Expert Review: Management of bleeding gastric varices
The evidence-based advice includes the following:
- Initial therapy for bleeding gastric varices should focus on acute hemostasis for hemodynamic stabilization with a plan for further diagnostic evaluation and/or transfer to a tertiary care center with expertise in gastric varices management.
- Following initial endoscopic hemostasis, cross-sectional (magnetic resonance or CT) imaging with portal venous contrast phase should be obtained to determine vascular anatomy, including the presence or absence of portosystemic shunts and gastrorenal shunts.
- Determination of definitive therapy for bleeding gastric varices should be based on endoscopic appearance of the gastric varix, the underlying vascular anatomy, presence of comorbid portal hypertensive complications, and available local resources. This is ideally done via a multidisciplinary discussion between the GI or hepatologist and the interventional radiologist.
In this AGA Clinical Practice Update Expert Review, the experts also suggest adding an estimate of variceal size and high-risk stigmata (discolored marks, platelet plugs) to the Sarin classification when describing patients’ gastric varices.
Read the full list of the best practice advice statements in the AGA Clinical Practice Update on Management of Bleeding Gastric Varices: Expert Review.
The evidence-based advice includes the following:
- Initial therapy for bleeding gastric varices should focus on acute hemostasis for hemodynamic stabilization with a plan for further diagnostic evaluation and/or transfer to a tertiary care center with expertise in gastric varices management.
- Following initial endoscopic hemostasis, cross-sectional (magnetic resonance or CT) imaging with portal venous contrast phase should be obtained to determine vascular anatomy, including the presence or absence of portosystemic shunts and gastrorenal shunts.
- Determination of definitive therapy for bleeding gastric varices should be based on endoscopic appearance of the gastric varix, the underlying vascular anatomy, presence of comorbid portal hypertensive complications, and available local resources. This is ideally done via a multidisciplinary discussion between the GI or hepatologist and the interventional radiologist.
In this AGA Clinical Practice Update Expert Review, the experts also suggest adding an estimate of variceal size and high-risk stigmata (discolored marks, platelet plugs) to the Sarin classification when describing patients’ gastric varices.
Read the full list of the best practice advice statements in the AGA Clinical Practice Update on Management of Bleeding Gastric Varices: Expert Review.
The evidence-based advice includes the following:
- Initial therapy for bleeding gastric varices should focus on acute hemostasis for hemodynamic stabilization with a plan for further diagnostic evaluation and/or transfer to a tertiary care center with expertise in gastric varices management.
- Following initial endoscopic hemostasis, cross-sectional (magnetic resonance or CT) imaging with portal venous contrast phase should be obtained to determine vascular anatomy, including the presence or absence of portosystemic shunts and gastrorenal shunts.
- Determination of definitive therapy for bleeding gastric varices should be based on endoscopic appearance of the gastric varix, the underlying vascular anatomy, presence of comorbid portal hypertensive complications, and available local resources. This is ideally done via a multidisciplinary discussion between the GI or hepatologist and the interventional radiologist.
In this AGA Clinical Practice Update Expert Review, the experts also suggest adding an estimate of variceal size and high-risk stigmata (discolored marks, platelet plugs) to the Sarin classification when describing patients’ gastric varices.
Read the full list of the best practice advice statements in the AGA Clinical Practice Update on Management of Bleeding Gastric Varices: Expert Review.
Five reasons to update your will
You have a will, so you can rest easy, right? Not necessarily. If your will is outdated, it can actually cause more harm than good. Even though it can provide for some contingencies, an old will can’t cover every change that may have occurred since it was first drawn. Here are five reasons to update your will.
Keep it current
When life changes, so should your will. Ensure that this important document matches your current wishes by reviewing it every few years.
Take a look at what has changed
Professionals advise that you review your will every few years and more often if situations such as the following five have occurred since you last updated your will.
- Family changes. If you’ve had any changes in your family situation, you will probably need to update your will. Events such as marriage, divorce, death, birth, adoption, or a falling out with a loved one may affect how your estate will be distributed, who should act as guardian for your dependents, and who should be named as executor of your estate.
- Relocating to a new state. The laws among the states vary. Moving to a new state or purchasing property in another state can affect your estate plan and how property in that state will be taxed and distributed.
- Changes in your estate’s value. When you made your will, your assets may have been relatively modest. Now the value may be larger and your will no longer reflects how you would like your estate divided.
- Tax law changes. Federal and state legislatures are continually tinkering with federal estate and state inheritance tax laws. An old will may fail to take advantage of strategies that will minimize estate taxes.
- You want to support a favorite cause. If you have developed a connection to a cause, you may want to benefit a particular charity with a gift in your estate. Contact us for sample language you can share with your attorney to include a gift to us in your will.
Get the help you need
To make sure your will accomplishes all you intend, seek the help of an attorney who specializes in estate planning. Already finalized your charitable distribution to the AGA Research Foundation? Send us your letter of intent at foundation@gastro.org.
You have a will, so you can rest easy, right? Not necessarily. If your will is outdated, it can actually cause more harm than good. Even though it can provide for some contingencies, an old will can’t cover every change that may have occurred since it was first drawn. Here are five reasons to update your will.
Keep it current
When life changes, so should your will. Ensure that this important document matches your current wishes by reviewing it every few years.
Take a look at what has changed
Professionals advise that you review your will every few years and more often if situations such as the following five have occurred since you last updated your will.
- Family changes. If you’ve had any changes in your family situation, you will probably need to update your will. Events such as marriage, divorce, death, birth, adoption, or a falling out with a loved one may affect how your estate will be distributed, who should act as guardian for your dependents, and who should be named as executor of your estate.
- Relocating to a new state. The laws among the states vary. Moving to a new state or purchasing property in another state can affect your estate plan and how property in that state will be taxed and distributed.
- Changes in your estate’s value. When you made your will, your assets may have been relatively modest. Now the value may be larger and your will no longer reflects how you would like your estate divided.
- Tax law changes. Federal and state legislatures are continually tinkering with federal estate and state inheritance tax laws. An old will may fail to take advantage of strategies that will minimize estate taxes.
- You want to support a favorite cause. If you have developed a connection to a cause, you may want to benefit a particular charity with a gift in your estate. Contact us for sample language you can share with your attorney to include a gift to us in your will.
Get the help you need
To make sure your will accomplishes all you intend, seek the help of an attorney who specializes in estate planning. Already finalized your charitable distribution to the AGA Research Foundation? Send us your letter of intent at foundation@gastro.org.
You have a will, so you can rest easy, right? Not necessarily. If your will is outdated, it can actually cause more harm than good. Even though it can provide for some contingencies, an old will can’t cover every change that may have occurred since it was first drawn. Here are five reasons to update your will.
Keep it current
When life changes, so should your will. Ensure that this important document matches your current wishes by reviewing it every few years.
Take a look at what has changed
Professionals advise that you review your will every few years and more often if situations such as the following five have occurred since you last updated your will.
- Family changes. If you’ve had any changes in your family situation, you will probably need to update your will. Events such as marriage, divorce, death, birth, adoption, or a falling out with a loved one may affect how your estate will be distributed, who should act as guardian for your dependents, and who should be named as executor of your estate.
- Relocating to a new state. The laws among the states vary. Moving to a new state or purchasing property in another state can affect your estate plan and how property in that state will be taxed and distributed.
- Changes in your estate’s value. When you made your will, your assets may have been relatively modest. Now the value may be larger and your will no longer reflects how you would like your estate divided.
- Tax law changes. Federal and state legislatures are continually tinkering with federal estate and state inheritance tax laws. An old will may fail to take advantage of strategies that will minimize estate taxes.
- You want to support a favorite cause. If you have developed a connection to a cause, you may want to benefit a particular charity with a gift in your estate. Contact us for sample language you can share with your attorney to include a gift to us in your will.
Get the help you need
To make sure your will accomplishes all you intend, seek the help of an attorney who specializes in estate planning. Already finalized your charitable distribution to the AGA Research Foundation? Send us your letter of intent at foundation@gastro.org.
Top cases
Physicians with difficult patient scenarios regularly bring their questions to the AGA Community ( https://community.gastro.org ) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. Here’s a preview of a recent popular clinical discussion:
From Brock Doubledee, DO: Xeljanz for Crohn’s
“I have a 20-year-old female with moderately active Crohn’s disease who has now failed Humira, Remicade, Entyvio and Stelara. The only option I know of for her at this time is Xeljanz, however her insurance will not approve this medication given its lack of FDA approval. I would be interested to know if anyone has any other recommended options or has had success with getting insurance approval. If you have had success I would appreciate any articles or guidance you have utilized to gain this approval.”
See how AGA members responded and join the discussion: https://community.gastro.org/posts/24445.
Physicians with difficult patient scenarios regularly bring their questions to the AGA Community ( https://community.gastro.org ) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. Here’s a preview of a recent popular clinical discussion:
From Brock Doubledee, DO: Xeljanz for Crohn’s
“I have a 20-year-old female with moderately active Crohn’s disease who has now failed Humira, Remicade, Entyvio and Stelara. The only option I know of for her at this time is Xeljanz, however her insurance will not approve this medication given its lack of FDA approval. I would be interested to know if anyone has any other recommended options or has had success with getting insurance approval. If you have had success I would appreciate any articles or guidance you have utilized to gain this approval.”
See how AGA members responded and join the discussion: https://community.gastro.org/posts/24445.
Physicians with difficult patient scenarios regularly bring their questions to the AGA Community ( https://community.gastro.org ) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. Here’s a preview of a recent popular clinical discussion:
From Brock Doubledee, DO: Xeljanz for Crohn’s
“I have a 20-year-old female with moderately active Crohn’s disease who has now failed Humira, Remicade, Entyvio and Stelara. The only option I know of for her at this time is Xeljanz, however her insurance will not approve this medication given its lack of FDA approval. I would be interested to know if anyone has any other recommended options or has had success with getting insurance approval. If you have had success I would appreciate any articles or guidance you have utilized to gain this approval.”
See how AGA members responded and join the discussion: https://community.gastro.org/posts/24445.
Get to know this year’s Julius Friedenwald Medal recipient: Dr. Michael Camilleri
In last month’s Gastroenterology, Vijay H. Shah, MD, and colleagues share a commentary on the esteemed career of this year’s Julius Friedenwald Medal recipient, Michael Camilleri, MD, of the Mayo Clinic in Rochester, Minnesota. Here are some fun facts about this year’s honoree:
- While growing up in Malta, he was influenced by a combination of his uncle, a kindly family physician, and by watching the shows Dr. Kildare and Marcus Welby, M.D., on a black-and-white television set during his childhood, which led Dr. Camilleri to commit to a career in medicine by the age of 8.
- Dr. Camilleri started his journey at the Mayo Clinic as a research fellow in 1983 conducting fundamental clinical research in GI motility.
- With 660 peer-reviewed original articles and 290 published invited reviews and editorial publications, Dr. Camilleri has redefined the understanding and treatment of disorders covering the entire GI tract from rumination syndrome to pelvic dyssynergia.
- Dr. Camilleri has mentored 79 postdoctoral fellows since he joined the faculty at Mayo Clinic 35 years ago.
Read more about Dr. Camilleri’s life and contribution to the GI community in this Gastroenterology commentary, written by his colleagues and friends, including Dr. Shah and Adil E. Bharucha, MBBS, MD; David A. Katzka, MD; and Gregory J. Gores, MD.
In last month’s Gastroenterology, Vijay H. Shah, MD, and colleagues share a commentary on the esteemed career of this year’s Julius Friedenwald Medal recipient, Michael Camilleri, MD, of the Mayo Clinic in Rochester, Minnesota. Here are some fun facts about this year’s honoree:
- While growing up in Malta, he was influenced by a combination of his uncle, a kindly family physician, and by watching the shows Dr. Kildare and Marcus Welby, M.D., on a black-and-white television set during his childhood, which led Dr. Camilleri to commit to a career in medicine by the age of 8.
- Dr. Camilleri started his journey at the Mayo Clinic as a research fellow in 1983 conducting fundamental clinical research in GI motility.
- With 660 peer-reviewed original articles and 290 published invited reviews and editorial publications, Dr. Camilleri has redefined the understanding and treatment of disorders covering the entire GI tract from rumination syndrome to pelvic dyssynergia.
- Dr. Camilleri has mentored 79 postdoctoral fellows since he joined the faculty at Mayo Clinic 35 years ago.
Read more about Dr. Camilleri’s life and contribution to the GI community in this Gastroenterology commentary, written by his colleagues and friends, including Dr. Shah and Adil E. Bharucha, MBBS, MD; David A. Katzka, MD; and Gregory J. Gores, MD.
In last month’s Gastroenterology, Vijay H. Shah, MD, and colleagues share a commentary on the esteemed career of this year’s Julius Friedenwald Medal recipient, Michael Camilleri, MD, of the Mayo Clinic in Rochester, Minnesota. Here are some fun facts about this year’s honoree:
- While growing up in Malta, he was influenced by a combination of his uncle, a kindly family physician, and by watching the shows Dr. Kildare and Marcus Welby, M.D., on a black-and-white television set during his childhood, which led Dr. Camilleri to commit to a career in medicine by the age of 8.
- Dr. Camilleri started his journey at the Mayo Clinic as a research fellow in 1983 conducting fundamental clinical research in GI motility.
- With 660 peer-reviewed original articles and 290 published invited reviews and editorial publications, Dr. Camilleri has redefined the understanding and treatment of disorders covering the entire GI tract from rumination syndrome to pelvic dyssynergia.
- Dr. Camilleri has mentored 79 postdoctoral fellows since he joined the faculty at Mayo Clinic 35 years ago.
Read more about Dr. Camilleri’s life and contribution to the GI community in this Gastroenterology commentary, written by his colleagues and friends, including Dr. Shah and Adil E. Bharucha, MBBS, MD; David A. Katzka, MD; and Gregory J. Gores, MD.
AGA, GI societies support lowering CRC screening age
American Gastroenterological Association, American College of Gastroenterology, and American Society for Gastrointestinal Endoscopy issued a statement of support that also notes our Multi-Society Task Force on Colorectal Cancer is finalizing our own recommendation to start screening at 45 years of age as well.
Incoming AGA President John M. Inadomi, MD, AGAF, notes that, “We expect this important change to save lives and improve the health of the U.S. population.”
AGA fully supports the decision of the U.S. Preventive Services Task Force to reduce the age at which to initiate screening among individuals at average risk for development of colorectal cancer to 45 years. This decision harmonizes the recommendations between the major U.S. screening guidelines including the American Cancer Society and American College of Physicians.
“The analysis by the USPSTF is timely and incredibly helpful to population health and to gastroenterologists and other providers,” says Bishr Omary, MD, PhD, AGAF, president of AGA. “We now have clear guidance to start colorectal cancer screening at age 45 for those with average risk and discontinue screening after age 85.”
American Gastroenterological Association, American College of Gastroenterology, and American Society for Gastrointestinal Endoscopy issued a statement of support that also notes our Multi-Society Task Force on Colorectal Cancer is finalizing our own recommendation to start screening at 45 years of age as well.
Incoming AGA President John M. Inadomi, MD, AGAF, notes that, “We expect this important change to save lives and improve the health of the U.S. population.”
AGA fully supports the decision of the U.S. Preventive Services Task Force to reduce the age at which to initiate screening among individuals at average risk for development of colorectal cancer to 45 years. This decision harmonizes the recommendations between the major U.S. screening guidelines including the American Cancer Society and American College of Physicians.
“The analysis by the USPSTF is timely and incredibly helpful to population health and to gastroenterologists and other providers,” says Bishr Omary, MD, PhD, AGAF, president of AGA. “We now have clear guidance to start colorectal cancer screening at age 45 for those with average risk and discontinue screening after age 85.”
American Gastroenterological Association, American College of Gastroenterology, and American Society for Gastrointestinal Endoscopy issued a statement of support that also notes our Multi-Society Task Force on Colorectal Cancer is finalizing our own recommendation to start screening at 45 years of age as well.
Incoming AGA President John M. Inadomi, MD, AGAF, notes that, “We expect this important change to save lives and improve the health of the U.S. population.”
AGA fully supports the decision of the U.S. Preventive Services Task Force to reduce the age at which to initiate screening among individuals at average risk for development of colorectal cancer to 45 years. This decision harmonizes the recommendations between the major U.S. screening guidelines including the American Cancer Society and American College of Physicians.
“The analysis by the USPSTF is timely and incredibly helpful to population health and to gastroenterologists and other providers,” says Bishr Omary, MD, PhD, AGAF, president of AGA. “We now have clear guidance to start colorectal cancer screening at age 45 for those with average risk and discontinue screening after age 85.”
The 2021-2022 research awards cycle is now open
We are pleased to announce that the AGA Research Foundation’s research awards cycle is now open.
The cycle begins with our two specialty awards focused on digestive and gastric cancers – applications are due on July 21.
AGA–Caroline Craig Augustyn & Damian Augustyn Award in Digestive Cancer: One $40,000 award supports an early career investigator who holds a career development award devoted to digestive cancer research.
AGA–R. Robert & Sally Funderburg Research Award in Gastric Cancer One $100,000 award supports an established investigator working on novel approaches in gastric cancer research.
In addition to our usual awards portfolio focused on a broad range of digestive diseases, we have established several new awards that will fund research focused on health and health care disparities. Click on the links below to learn more about each award and application requirements.
- Pilot Research Awards: Currently accepting applications
- Research Scholar Awards: Open Aug. 12
We are pleased to announce that the AGA Research Foundation’s research awards cycle is now open.
The cycle begins with our two specialty awards focused on digestive and gastric cancers – applications are due on July 21.
AGA–Caroline Craig Augustyn & Damian Augustyn Award in Digestive Cancer: One $40,000 award supports an early career investigator who holds a career development award devoted to digestive cancer research.
AGA–R. Robert & Sally Funderburg Research Award in Gastric Cancer One $100,000 award supports an established investigator working on novel approaches in gastric cancer research.
In addition to our usual awards portfolio focused on a broad range of digestive diseases, we have established several new awards that will fund research focused on health and health care disparities. Click on the links below to learn more about each award and application requirements.
- Pilot Research Awards: Currently accepting applications
- Research Scholar Awards: Open Aug. 12
We are pleased to announce that the AGA Research Foundation’s research awards cycle is now open.
The cycle begins with our two specialty awards focused on digestive and gastric cancers – applications are due on July 21.
AGA–Caroline Craig Augustyn & Damian Augustyn Award in Digestive Cancer: One $40,000 award supports an early career investigator who holds a career development award devoted to digestive cancer research.
AGA–R. Robert & Sally Funderburg Research Award in Gastric Cancer One $100,000 award supports an established investigator working on novel approaches in gastric cancer research.
In addition to our usual awards portfolio focused on a broad range of digestive diseases, we have established several new awards that will fund research focused on health and health care disparities. Click on the links below to learn more about each award and application requirements.
- Pilot Research Awards: Currently accepting applications
- Research Scholar Awards: Open Aug. 12
The gift you should be talking about
If you want to make a lasting impact at the AGA Research Foundation, one of the easiest ways is to name us as a beneficiary of one of your assets, such as your retirement plan, life insurance policy, bank account, or donor-advised fund.
When you do, don’t forget to notify us of your decisions. Many charities and individuals aren’t aware that they have been named to receive a gift. Informing them helps preserve your intentions and ensures that your beneficiaries are able to follow your wishes.
Steps to protect the people and charities you love
- Review your beneficiary designations periodically because circumstances change throughout your lifetime.
- Alert your beneficiaries that you have a life insurance policy or have named them as beneficiaries of a retirement plan.
- Share the location and details of the policy or plan with your beneficiaries.
As you update your beneficiary designations, consider making a gift of a life insurance policy or retirement plan to the AGA Research Foundation so that we can continue to progress with our mission. Then let us know about your decision so that we can carry out your wishes as intended and thank you for your gift.
We want to hear from you
If you have already named the AGA Research Foundation as a beneficiary of a life insurance policy or retirement plan assets, please contact us at foundation@gastro.org today. If you are still creating your estate plan, we would be happy to answer any questions you may have about making this type of gift.
If you want to make a lasting impact at the AGA Research Foundation, one of the easiest ways is to name us as a beneficiary of one of your assets, such as your retirement plan, life insurance policy, bank account, or donor-advised fund.
When you do, don’t forget to notify us of your decisions. Many charities and individuals aren’t aware that they have been named to receive a gift. Informing them helps preserve your intentions and ensures that your beneficiaries are able to follow your wishes.
Steps to protect the people and charities you love
- Review your beneficiary designations periodically because circumstances change throughout your lifetime.
- Alert your beneficiaries that you have a life insurance policy or have named them as beneficiaries of a retirement plan.
- Share the location and details of the policy or plan with your beneficiaries.
As you update your beneficiary designations, consider making a gift of a life insurance policy or retirement plan to the AGA Research Foundation so that we can continue to progress with our mission. Then let us know about your decision so that we can carry out your wishes as intended and thank you for your gift.
We want to hear from you
If you have already named the AGA Research Foundation as a beneficiary of a life insurance policy or retirement plan assets, please contact us at foundation@gastro.org today. If you are still creating your estate plan, we would be happy to answer any questions you may have about making this type of gift.
If you want to make a lasting impact at the AGA Research Foundation, one of the easiest ways is to name us as a beneficiary of one of your assets, such as your retirement plan, life insurance policy, bank account, or donor-advised fund.
When you do, don’t forget to notify us of your decisions. Many charities and individuals aren’t aware that they have been named to receive a gift. Informing them helps preserve your intentions and ensures that your beneficiaries are able to follow your wishes.
Steps to protect the people and charities you love
- Review your beneficiary designations periodically because circumstances change throughout your lifetime.
- Alert your beneficiaries that you have a life insurance policy or have named them as beneficiaries of a retirement plan.
- Share the location and details of the policy or plan with your beneficiaries.
As you update your beneficiary designations, consider making a gift of a life insurance policy or retirement plan to the AGA Research Foundation so that we can continue to progress with our mission. Then let us know about your decision so that we can carry out your wishes as intended and thank you for your gift.
We want to hear from you
If you have already named the AGA Research Foundation as a beneficiary of a life insurance policy or retirement plan assets, please contact us at foundation@gastro.org today. If you are still creating your estate plan, we would be happy to answer any questions you may have about making this type of gift.
Top cases
Physicians with difficult patient scenarios regularly bring their questions to the AGA Community (https://community.gastro.org) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. Here’s a preview of a recent popular clinical discussion:
From Rafael Ching Companioni, MD: Malnutrition, elevated liver enzymes, anemia, and malabsorption
“Early 30 year-old female who was initially referred to GI in December 2020 for abnormal liver enzymes ALT 263, AST 114, alk phosp 212, albumin 3.2, bili [within normal limits]. At that time, she reports some diarrhea, few episodes of diarrhea per day, diffuse abdominal pain, ~20 LBs weight loss. She denied herbal medications, OTC medications or other medications. Last travel was 2 years ago to England. No history of anorexia nervosa or bulimia. On examination, cachexia and extremity edema. She has iron deficiency anemia and reactive thrombocytosis. Her initial lipid panel in November 2020, the lipid panel shows total cholesterol 208, LDL 113, triglycerides 227.
“She is still losing weight: 20 lbs from Feb 2021. The liver enzymes elevation resolved. She has anemia, malnutrition and malabsorption. I recommended gluten free diet, MVI, iron pills, protein bars. I had ordered scleroderma workup and SIBO tests today. I am planning to do MRE.”
See how AGA members responded and join the discussion: https://community.gastro.org/posts/24416.
Physicians with difficult patient scenarios regularly bring their questions to the AGA Community (https://community.gastro.org) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. Here’s a preview of a recent popular clinical discussion:
From Rafael Ching Companioni, MD: Malnutrition, elevated liver enzymes, anemia, and malabsorption
“Early 30 year-old female who was initially referred to GI in December 2020 for abnormal liver enzymes ALT 263, AST 114, alk phosp 212, albumin 3.2, bili [within normal limits]. At that time, she reports some diarrhea, few episodes of diarrhea per day, diffuse abdominal pain, ~20 LBs weight loss. She denied herbal medications, OTC medications or other medications. Last travel was 2 years ago to England. No history of anorexia nervosa or bulimia. On examination, cachexia and extremity edema. She has iron deficiency anemia and reactive thrombocytosis. Her initial lipid panel in November 2020, the lipid panel shows total cholesterol 208, LDL 113, triglycerides 227.
“She is still losing weight: 20 lbs from Feb 2021. The liver enzymes elevation resolved. She has anemia, malnutrition and malabsorption. I recommended gluten free diet, MVI, iron pills, protein bars. I had ordered scleroderma workup and SIBO tests today. I am planning to do MRE.”
See how AGA members responded and join the discussion: https://community.gastro.org/posts/24416.
Physicians with difficult patient scenarios regularly bring their questions to the AGA Community (https://community.gastro.org) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. Here’s a preview of a recent popular clinical discussion:
From Rafael Ching Companioni, MD: Malnutrition, elevated liver enzymes, anemia, and malabsorption
“Early 30 year-old female who was initially referred to GI in December 2020 for abnormal liver enzymes ALT 263, AST 114, alk phosp 212, albumin 3.2, bili [within normal limits]. At that time, she reports some diarrhea, few episodes of diarrhea per day, diffuse abdominal pain, ~20 LBs weight loss. She denied herbal medications, OTC medications or other medications. Last travel was 2 years ago to England. No history of anorexia nervosa or bulimia. On examination, cachexia and extremity edema. She has iron deficiency anemia and reactive thrombocytosis. Her initial lipid panel in November 2020, the lipid panel shows total cholesterol 208, LDL 113, triglycerides 227.
“She is still losing weight: 20 lbs from Feb 2021. The liver enzymes elevation resolved. She has anemia, malnutrition and malabsorption. I recommended gluten free diet, MVI, iron pills, protein bars. I had ordered scleroderma workup and SIBO tests today. I am planning to do MRE.”
See how AGA members responded and join the discussion: https://community.gastro.org/posts/24416.